The U.S. Food and Drug Administration announced the first nine awardees of the Commissioner’s National Priority Voucher (CNPV) pilot program, which aims to accelerate review for products addressing national priorities or unmet needs. The initial cohort includes small molecules, gene therapies and rare‑disease candidates; companies awarded the vouchers could receive regulatory decisions in as little as one to two months. Industry reaction was immediate: stocks of some recipients moved on the news and sponsors signaled plans to leverage the program to compress timelines and capture earlier market access.